Wilson's Disease
2
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
OrphalanFrance - Paris
3 programs1
1
New TETA 4HCl FormulationPhase 21 trial
900mg TETA 4HCl Once Daily FormulationPhase 11 trial
International Wilson's Disease Patient Registry (iWilson Registry)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
OrphalanNew TETA 4HCl Formulation
Orphalan900mg TETA 4HCl Once Daily Formulation
OrphalanInternational Wilson's Disease Patient Registry (iWilson Registry)
Clinical Trials (3)
Total enrollment: 536 patients across 3 trials
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
Start: Jul 2025Est. completion: Dec 202510 patients
Phase 2Completed
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
Start: Jan 2024Est. completion: Feb 202426 patients
Phase 1Completed
International Wilson's Disease Patient Registry (iWilson Registry)
Start: Jun 2022Est. completion: Dec 2027500 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 536 patients
1 companies competing in this space